|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 295/15 | (2006.01) |
| C07D 295/15 | (2013.01) | ||
| A61P 1/00 | (2006.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 1/02 | (2018.01) | ||
| A61P 31/00 | (2006.01) | ||
| A61P 13/02 | (2018.01) | ||
| A61K 31/65 | (2006.01) | ||
| A61P 31/00 | (2018.01) | ||
| A61P 1/02 | (2006.01) | ||
| A61P 31/04 | (2018.01) | ||
| A61P 31/04 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 13/02 | (2006.01) |
| (11) | Number of the document | 3529236 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17794505.2 |
| Date of filing the European patent application | 2017-10-19 | |
| (97) | Date of publication of the European application | 2019-08-28 |
| (45) | Date of publication and mention of the grant of the patent | 2024-02-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/057385 |
| Date | 2017-10-19 |
| (87) | Number | WO 2018/075767 |
| Date | 2018-04-26 |
| (30) | Number | Date | Country code |
| 201662410230 P | 2016-10-19 | US |
| (72) |
LAFRANCE, Danny , US
HOGAN, Philip, C. , US
LIU, Yansheng , US
HE, Minsheng , US
CHEN, Chi-Li , US
NIU, John , US
|
| (73) |
Tetraphase Pharmaceuticals, Inc. ,
35 Gatehouse Drive, Suite E0, Waltham, MA 02451,
US
|
| (54) | CRYSTALLINE FORMS OF ERAVACYCLINE |
| CRYSTALLINE FORMS OF ERAVACYCLINE |